Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends

International Journal of Cancer

Volumn 141, Issue 10, 2017, Pages 1997-2001

  Vaccarella, S ^a   Laversanne, M ^a   Ferlay, J ^a   Bray, F ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

cervical cancer; incidence and mortality trends; screening; vaccination

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

AFRICA; ARTICLE; ASIA; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CARIBBEAN; CAUSE OF DEATH; CONTROLLED STUDY; EARLY CANCER DIAGNOSIS; FEMALE; GLOBAL DISEASE BURDEN; HEALTH CARE DISPARITY; HUMAN; MUSLIM; PRIORITY JOURNAL; RISK FACTOR; SOUTH AND CENTRAL AMERICA; TREND STUDY; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; AGED; CANCER STAGING; CHILD; DEVELOPING COUNTRY; FOLLOW UP; INCIDENCE; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; SOCIOECONOMICS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85029601602     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30901     Document Type: Article

References (21)

1. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607–15.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.
3. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 5:F123–F38.
4. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013;10:400–10.
5. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1–670.
6. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30 Suppl 5:F88–99.
7. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 2012;13:790–801.
8. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Accessed July 27, 2016. Available at http://globocan.iarc.fr.
9. Vaccarella S, Lortet-Tieulent J, Plummer M, et al. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49:3262–73.
10. Vaccarella S, Franceschi S, Engholm G, et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014;111:965–9.
11. Vaccarella S, Franceschi S, Zaridze D, et al. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017–40: a population-based study. Lancet Oncol 2016;17:1445–52.
12. Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 2014;136:2752-6.
13. IARC. CI5 - Cancer Incidence in Five Continents, Vol. X. IARC Scientific Publication No. 164. Lyon, France: International Agency for Research on Cancer, 2014.
14. Parkin DM, Bray F, Ferlay J, et al. Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev 2014;23:953–66.
15. de Vuyst H, Alemany L, Lacey C, et al. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013;31 Suppl 5:F32–46.
16. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789–99.
17. Wabinga HR, Nambooze S, Amulen PM, et al. Trends in the incidence of cancer in Kampala, Uganda 1991–2010. Int J Cancer 2014;135:432–9.
18. Chokunonga E, Borok MZ, Chirenje ZM, et al. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. Int J Cancer 2013;133:721–9.
19. Vaccarella S, Bruni L, Seoud M. Burden of human papillomavirus infections and related diseases in the extended Middle East and North Africa region. Vaccine 2013;31 Suppl 6:G32–44.
20. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32.
21. Bosch FX, Robles C, Diaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119–32.